Consensus Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
959.9 USD -0.47% Intraday chart for Regeneron Pharmaceuticals, Inc. -0.47% +9.29%

Evolution of the average Target Price on Regeneron Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

c5220c5308419661f33230a2.l-GaI8c3SJlVN3pf7jiulza5WSSM48dmk13HwOaxkTc.wdHUDvRnF68zT0g81lnL4U7qBkfVuZAS4jqUmrf4xnCgu7d89EYL0TlkCQ~5b309ed9eb32557487abbf22809f63ac
Morgan Stanley Raises Price Target on Regeneron Pharmaceuticals to $1,115 From $1,104, Maintains Overweight Rating MT
RBC Raises Price Target on Regeneron Pharmaceuticals to $1,184 From $1,096, Keeps Outperform Rating MT
RBC Trims Price Target on Regeneron Pharmaceuticals to $1,096 From $1,110, Keeps Outperform Rating MT
Cantor Fitzgerald Adjusts Price Target on Regeneron Pharmaceuticals to $925 From $850, Keeps Neutral Rating MT
UBS Adjusts Price Target on Regeneron Pharmaceuticals to $1,090 from $1,112, Maintains Buy Rating MT
Deutsche Bank Adjusts Price Target on Regeneron Pharmaceuticals to $880 From $870, Maintains Hold Rating MT
Truist Adjusts Price Target on Regeneron Pharmaceuticals to $1,135 From $1,045, Maintains Buy Rating MT
RBC Lifts Price Target on Regeneron Pharmaceuticals to $1,110 From $1,076 Amid 'Underappreciated' Growth Prospects for Dupixent; Outperform Kept MT
Barclays Adjusts Regeneron Pharmaceuticals' Price Target to $1,050 From $1,020, Keeps Overweight Rating MT
Piper Sandler Adjusts Regeneron Pharmaceuticals' Price Target to $1,016 From $956, Keeps Overweight Rating MT
Wells Fargo Adjusts Regeneron Pharmaceuticals' Price Target to $1,050 From $980, Keeps Overweight Rating MT
Goldman Sachs Adjusts Regeneron Pharmaceuticals' Price Target to $1,135 From $1,045, Keeps Buy Rating MT
Goldman Sachs Adjusts Regeneron Pharmaceuticals' Price Target to $1,083 From $1,007, Keeps Buy Rating MT
BMO Capital Adjusts Regeneron Pharmaceuticals' Price Target to $1,082 From $1,055, Keeps Outperform Rating MT
Canaccord Genuity Adjusts Regeneron Pharmaceuticals' Price Target to $1,152 From $1,066, Keeps Buy Rating MT
Baird Adjusts Regeneron Pharmaceuticals' Price Target to $940 From $797, Keeps Neutral Rating MT
Job data is good for the economy, not for rate cuts Our Logo
Wedbush Raises 2seventy bio's PT to $5 From $2 After Announced Sale of Research, Development Projects to Regeneron, Keeps Neutral Rating MT
Deutsche Bank Raises Regeneron Pharmaceuticals Price Target to $870 From $800, Maintains Hold Rating MT
BofA Securities Raises Regeneron Pharmaceuticals Price Target to $710 From $700, Maintains Underperform Rating MT
Barclays Raises Price Target on Regeneron Pharmaceuticals to $1,020 From $935, Keeps Overweight Rating MT
RBC Upgrades Regeneron Pharmaceuticals to Outperform From Sector Perform, Boosts Price Target to $1,076 From $884 MT
ANALYST RECOMMENDATIONS : Bunzl, Netflix, Snowflake, Dr Horton, Wpp... Our Logo
Investors lower their expectations Our Logo
RBC Raises Price Target on Regeneron Pharmaceuticals to $884 From $837, Keeps Sector Perform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
959.9 USD
Average target price
1,017 USD
Spread / Average Target
+5.97%
High Price Target
1,184 USD
Spread / Highest target
+23.34%
Low Price Target
710 USD
Spread / Lowest Target
-26.04%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Regeneron Pharmaceuticals, Inc.

Morgan Stanley
RBC Capital Markets
Cantor Fitzgerald
UBS
Deutsche Bank Securities
Truist Securities
Barclays
Piper Sandler
Wells Fargo Securities
Goldman Sachs
BMO Capital
Canaccord Genuity
Baird
BofA Securities
TD Cowen
Jefferies & Co.
Raymond James
WestPark Capital
Oppenheimer
Guggenheim
JPMorgan Chase
SVB Securities LLC
EF Hutton
Cowen
Evercore ISI
Argus
Bernstein
Benchmark Capital
HC Wainwright
SVB Leerink
Credit Suisse
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
  1. Stock
  2. Equities
  3. Stock Regeneron Pharmaceuticals, Inc. - Nasdaq
  4. Consensus Regeneron Pharmaceuticals, Inc.